More than 10 billion U.S. dollars of lysovirus market The latest developments in The country at a glance.

MEDICINE NETWORK, Oct. 9 (Xinhua) -- Lyovirus is one of the most cutting-edge treatments for tumors in the world, capable of replicating specifically within tumor cells and causing cell cleavage without affecting normal cells.
-soluble tumor virus further enhances the immune response by reconstructing the immune response of tumor micro-environment, combined with recombinant expression of IL-12, PD-1 antibodies, GM-CSF, etc., and plays an immune killing purpose on tumor cells.
currently, one of the strategies for the transformation of lysovirus is to form combination therapies with other cancer drugs to enhance immune activity.
statistics, the future of the lysovirus field can reach more than 10 billion U.S. dollars of the market, attracting domestic pharmaceutical companies have been laid out.
to date, seven lysovirus products have entered the market in different ways and in different regions.
overall, companies developing lysovirus are concentrated in Europe and the United States, and are concentrated in small or emerging biotech companies, with large pharmaceutical companies acquiring lysovirus research and development pipelines primarily through introduction or acquisition.
about 10 enterprises in China are involved in lysovirus, and self-research or introduction of products are in the clinical stage.
incomplete statistics, there are currently more than 100 clinical trials of the lysovirus currently under way worldwide.
the development of domestic lysovirus in 2020 is also in full swing, including Sino-Japanese rehabilitation, binobiology and other pharmaceutical companies related products were approved clinically.
To meet the difficulties, the future can be phased in the recovery of noovirus September 17, the VG161 of meso-resuscant resuscant health organisms in China was approved clinically, intended to be developed for the treatment of late-stage malignant solid tumors with injectable lesions.
it is known that VG161 is a new type of anti-tumor immuno-enhanced type I herpes-soluble virus with fully independent intellectual property rights, which carries both IL12, IL15/15RA (IL15 and IL15 subjects α aki) and PD-L1 blocker peptides (PDL1B), the world's first products carrying four immunokines.
VG161 is injected into tumor tissue through intra-tumor injection, and the virus replicates and dissolves tumor cells in tumor cells, while carrying four immunostational stimulation factors are effectively expressed, realizing the synergy between tumor lysolytic activity and immunostational stimulation.
, further synergies occurred between the four immunostatoxic factors expressed by the virus, which transformed the antiviral immune response into a specific anti-tumor immune response.
also announced the completion of round C financing, raising a total of $62 million.
this round of financing will be used for clinical advances in existing product pipelines, preclinical studies of early research and development projects, and potential collaborative projects.
Wuhan Binzhou Bin association biotech recombinant person GM-CSF lysoma type II herpes simplex virus (OH2) injection (Vero cells) combined PD-1/L1 treatment can not be surgically removed, standard treatment failure of advanced solid tumors (such as breast cancer, melanoma, head and neck cancer, soft tissue sarcoma, liver cancer or liver metastasis tumor, etc.) treatment.
Combined with Taizhou Han zhong bio-recombinant humanized anti-PD-1 monoclonal antibody injection, for non-surgical removal, standard treatment of failed advanced solid tumors (e.g. breast cancer, melanoma, head and neck cancer, soft tissue sarcoma, liver cancer or liver metastatic tumors, etc.) treatment.
combined with Theoco LP002 injection in Taizhou to treat advanced solid tumors (e.g. breast cancer, melanoma, head and neck cancer, soft tissue sarcoma, etc.) that are easily injected after standard treatment has failed.
, Bin club biotechnology OH2 injection single drug has entered the phase II clinical stage, and the joint use with PD-1/L1, is the first approved clinical.
Tianshi Li-Seinjie recombinant tumor pox virus injection T601 is a new class 1 drug developed in China by Tianshili's Genesis Company with fully independent intellectual property rights for therapeutic biological products, is a newly developed and designed lysate virus products, adaptive disease for the late malignant digestive tract solid tumor.
T601 has the dual effect of targeted lysoma and targeted chemotherapy, through genetic modification of wild pox virus, to achieve the role of targeted lysoma, in killing tumor cells and tumor tissue at the same time, will not cause damage to normal cells and tissues;
active layout, the listing is expected to be in addition to the above mentioned, the domestic also includes Alsoo Micro, Health Hall, Oyuan and Li, including the company is currently conducting clinical research on lysovirus, and hopefully approved for listing.
01 Alsono micropharmaceutical T3011 is a new generation of recombinant herpes lysoma virus developed by also norovirus, can be directly injected into the tumor treatment, and can be used to treat local late stage, recurrence or metastasis solid tumor anti-tumor drugs.
T3011 adopts the proprietary viral skeleton of Ino micro-medicine, which improves the replication and anti-tumor ability of the virus while taking into account the safety.
the cytokine combination IL-12 and Anti-PD-1 antibodies inserted by T3011 have novelty and clinical rationality, which can further enhance the immune synergetic anti-tumor effect.
In July 2019, T3011 was approved for clinical trials, and in May this year, intra-tumor injection was approved by the FDA in the United States, and clinical trials are now under way in China and Australia, making it the first company in the world to conduct clinical trials in China, the United States and Australia at the same time.
September 23rd, Ino micro announced the signing of a $10 million B-plus round of strategic financing, funded entirely by Shanghai Medical Capital (SHC) for the development of potential cancer treatment drugs.
02 Health Hall in October 2019 Zhejiang Health Hall independently developed injection recombinant human PD-1 antibody herpes simplex virus was approved for clinical use in head and neck cancer, lung cancer, colorectal cancer, melanoma, cervical cancer, bladder cancer, pancreatic cancer, liver cancer and other infusable intra-tumor injection, intravenous drip or thoracic/abdominal locally administered malignancies.
is currently in clinical phase I.
03 OrienX010 is a new gene therapy drug developed by Oyuan and Li with herpes simplex virus as the carrier, and has its own intellectual property rights, is the first clinical approval of the use of lysoma virus to treat tumor drugs, has been supported by the Ministry of Health's national major new drug creation project.
OrienX010 is a recombinant and detoxifying replica type I herpes simplex virus-soluble vector, orienX010 genome removed the disease-caused gene of HSV-1 and inserted encoded human GM -CSF DNA fragments, can selectively replicate the virus in tumor cells, leading to tumor cell cleavage death, while releasing tumor antigens, and through the carrier expression of GM-CSF protein to activate the systemic anti-tumor antigen specific immune response.
Recently, Professor Sr. S. S. from Guo Legion Team of Beijing Cancer Hospital presented clinical IB data in patients with fully removable Stage III and Phase IV (M1a) melanoma in the recombinant GM-CSF herpes simplex virus injection (OrienX010) in conjunction with Terripri monoantigen (PD-1 monoantigen) treatment, which showed good preoperative aids and safety.
addition, there are 3 products in Clinical Phase III.phase and 38 products in Clinical Phase II. According to the reported clinical data, the better efficacy is Ano Pharmaceuticals Reolysin (Clinical III.Phase III. Phase), Tiandakang gene ADV -TK (Clinical Phase III.), Genelux's GL-ONC1 (Clinical Phase II.Phase), ONCOLYS' OBP-301 (Clinical Phase II.Phase), KH901 (Clinical Phase II.) of Kanghong Bio, etc.
so far, the only products currently strictly approved on the market are 2015 FDA-approved Amgen's T-vec (Imlygic), the first FDA-approved treatment drug for melanoma patients.
with the joint program and the continuous improvement of the virus modification project, I believe that the next track of lysovirus will get more attention and layout of pharmaceutical companies.
good news about the lysovirus will follow.
.